Efficacy of Tacrolimus Versus Cyclosporine After Lung Transplantation: an Updated Systematic Review, Meta-analysis, and Trial Sequential Analysis of Randomized Controlled Trials

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2024 Sep 11

PMID 39261378

Authors

Husam Abu Suilik

Ali Saad Al-Shammari

Youssef Soliman

Mohamed Abu Suilik

Kamal A Naeim

Ahmad Nawlo

Mohamed Abuelazm

Affiliations

Soon will be listed here.

Abstract

Background: Little data supports using tacrolimus versus cyclosporin for immunosuppression concerning acute rejection and bronchiolitis obliterans syndrome/Chronic Lung Allograft Dysfunction CLAD complications following lung transplantation (LTx). Our goal was to evaluate the use of tacrolimus versus cyclosporine in preventing these complications after LTx.

Methods: We included randomized controlled trials (RCTs) by searching PubMed, Web of Science, SCOPUS, and Cochrane through January 10th, 2024. We pooled dichotomous data using the risk ratio (RR) and continuous data using the mean difference (MD) with a 95% confidence interval (CI).

Results: We included Four RCTs with a total of 677 patients. Tacrolimus was significantly associated with decreased risk of acute rejection (RR: 1.21, 95% CI [1.03, 1.42], I = 25%, P = 0.02) compared with cyclosporine, bronchiolitis obliterans syndrome/CLAD (RR: 1.87, 95% CI [1.26, 2.77], I = 52%, P = 0.002), and treatment withdrawal (RR: 3.11, 95% CI [2.06, 4.70], I = 0%, P = < 0.00001). However, tacrolimus significantly increased the risk of new-onset diabetes (RR: 0.33, 95% CI [0.12, 0.91], I = 0%, P = 0.03), and kidney dysfunction (RR: 0.79, 95% CI [0.66, 0.93], I = 0%, P = 0.006). In contrast, there was no difference in the incidence of all-cause mortality (RR: 91, 95% CI [0.68, 1.22], I = 0%, P = 0.53), arterial hypertension (RR: 2.40, 95% CI [0.41, 14.21], I = 92%, P = 0.33), and new cancer (RR: 1.57, 95% CI [0.79, 3.10], I = 4%, P = 0.20).

Conclusion: Tacrolimus has decreased acute rejection episodes and CLAD rate than cyclosporine, but it increased the risk of new-onset diabetes and kidney dysfunction.

References

Colombo D, Ammirati E . Cyclosporine in transplantation - a history of converging timelines. J Biol Regul Homeost Agents. 2012; 25(4):493-504. View

Bennett D, Fossi A, Marchetti L, Lanzarone N, Sisi S, Refini R . Postoperative acute kidney injury in lung transplant recipients. Interact Cardiovasc Thorac Surg. 2019; 28(6):929-935. DOI: 10.1093/icvts/ivy355. View

Penninga L, Moller C, Gustafsson F, Gluud C, Steinbruchel D . Immunosuppressive T-cell antibody induction for heart transplant recipients. Cochrane Database Syst Rev. 2013; (12):CD008842. PMC: 11559623. DOI: 10.1002/14651858.CD008842.pub2. View

Naci H, Davis C, Savovic J, Higgins J, Sterne J, Gyawali B . Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ. 2019; 366:l5221. PMC: 6749182. DOI: 10.1136/bmj.l5221. View

Guyatt G, Oxman A, Kunz R, Vist G, Falck-Ytter Y, Schunemann H . What is "quality of evidence" and why is it important to clinicians?. BMJ. 2008; 336(7651):995-8. PMC: 2364804. DOI: 10.1136/bmj.39490.551019.BE. View

Dellgren G, Lund T, Raivio P, Leuckfeld I, Svahn J, Holmberg E . Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial. Lancet Respir Med. 2023; 12(1):34-44. DOI: 10.1016/S2213-2600(23)00293-X. View

Hachem R, Yusen R, Chakinala M, Meyers B, Lynch J, Aloush A . A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant. 2007; 26(10):1012-8. DOI: 10.1016/j.healun.2007.07.027. View

Treede H, Glanville A, Klepetko W, Aboyoun C, Vettorazzi E, Lama R . Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant. 2012; 31(8):797-804. DOI: 10.1016/j.healun.2012.03.008. View

Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reichart B . Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg. 2003; 125(4):891-900. DOI: 10.1067/mtc.2003.71. View

10.

Lund L, Edwards L, Kucheryavaya A, Benden C, Dipchand A, Goldfarb S . The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015; 34(10):1244-54. DOI: 10.1016/j.healun.2015.08.003. View

11.

Hachem R, Khalifah A, Chakinala M, Yusen R, Aloush A, Mohanakumar T . The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation. 2005; 80(10):1406-13. DOI: 10.1097/01.tp.0000181161.60638.fa. View

12.

Darley D, Carlos L, Hennig S, Liu Z, Day R, Glanville A . Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection. Eur J Clin Pharmacol. 2019; 75(7):879-888. DOI: 10.1007/s00228-019-02658-5. View

13.

Horning N, Lynch J, Sundaresan S, Patterson G, Trulock E . Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant. 1998; 17(8):761-7. View

14.

Martinu T, Pavlisko E, Chen D, Palmer S . Acute allograft rejection: cellular and humoral processes. Clin Chest Med. 2011; 32(2):295-310. PMC: 3089893. DOI: 10.1016/j.ccm.2011.02.008. View

15.

Meiser B, Uberfuhr P, Fuchs A, Schulze C, Nollert G, Mair H . Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant. 1997; 16(8):795-800. View

16.

Haddad E, McAlister V, Renouf E, Malthaner R, Kjaer M, Gluud L . Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006; (4):CD005161. PMC: 8865611. DOI: 10.1002/14651858.CD005161.pub2. View

17.

Staatz C, Tett S . Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43(10):623-53. DOI: 10.2165/00003088-200443100-00001. View

18.

Morales J, Andres A, Rengel M, Rodicio J . Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 2001; 16 Suppl 1:121-4. DOI: 10.1093/ndt/16.suppl_1.121. View

19.

Taylor D, Barr M, Radovancevic B, Renlund D, Mentzer Jr R, Smart F . A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999; 18(4):336-45. DOI: 10.1016/s1053-2498(98)00060-6. View

20.

Chakkera H, Kudva Y, Kaplan B . Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus. Clin Pharmacol Ther. 2016; 101(1):114-120. DOI: 10.1002/cpt.546. View